PE20001597A1 - Solucion acuosa estable de em 12 (3-(1-oxo-1,3-dihidro-isoindol-2-il)-piperidin-2,6-diona), y procedimiento de preparacion de dicha solucion - Google Patents

Solucion acuosa estable de em 12 (3-(1-oxo-1,3-dihidro-isoindol-2-il)-piperidin-2,6-diona), y procedimiento de preparacion de dicha solucion

Info

Publication number
PE20001597A1
PE20001597A1 PE2000000251A PE0002512000A PE20001597A1 PE 20001597 A1 PE20001597 A1 PE 20001597A1 PE 2000000251 A PE2000000251 A PE 2000000251A PE 0002512000 A PE0002512000 A PE 0002512000A PE 20001597 A1 PE20001597 A1 PE 20001597A1
Authority
PE
Peru
Prior art keywords
solution
stable aqueous
preparation
aqueous solution
diona
Prior art date
Application number
PE2000000251A
Other languages
English (en)
Inventor
Heinrich Kugelmann
Tieno Germann
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19914621A external-priority patent/DE19914621C2/de
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20001597A1 publication Critical patent/PE20001597A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA SOLUCION ACUOSA ESTABLE DE UN DERIVADO DE TALIDOMIDA EM 12 (3-(1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL)-PIPERIDIN-2,6-DIONA); DE AL MENOS 0,2 mg/ml; CARACTERIZADO POR CONTENER EM 12 DISUELTO EN SOLUCION ISOTONICA DE GLUCOSA, SIENDO EL pH DE LA SOLUCION ¾ 5,5. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION DE UNA SOLUCION ACUOSA ESTABLE DEL DERIVADO DE TALIDOMIDA EM 12 PARA ADMINISTRACION PARENTERAL QUE COMPRENDE: DISOLVER DERIVADO DE TALIDOMIDA EM 12, EN UNA SOLUCION ISOTONICA DE GLUCOSA DE pH 4 A 5; MEZCLAR Y AGITAR HASTA DISOLUCION TOTAL PARA EL ACORTAMIENTO DEL TIEMPO DE PREPARACION; SE SOMETE A ULTRASONIDO Y SE FILTRA BAJO CONDICIONES ASEPTICAS. LA SOLUCION EN FORMA DE APLICACION PARENTERAL Y PUEDE SER UTILIZADA PARA LA TERAPIA DE ENFERMEDADES INFLAMATORIAS Y HEMATOLOGICO-ONCOLOGICAS
PE2000000251A 1999-03-31 2000-03-23 Solucion acuosa estable de em 12 (3-(1-oxo-1,3-dihidro-isoindol-2-il)-piperidin-2,6-diona), y procedimiento de preparacion de dicha solucion PE20001597A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19914621A DE19914621C2 (de) 1997-10-06 1999-03-31 Stabile wässrige Lösung von EM 12

Publications (1)

Publication Number Publication Date
PE20001597A1 true PE20001597A1 (es) 2001-01-20

Family

ID=7903088

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000251A PE20001597A1 (es) 1999-03-31 2000-03-23 Solucion acuosa estable de em 12 (3-(1-oxo-1,3-dihidro-isoindol-2-il)-piperidin-2,6-diona), y procedimiento de preparacion de dicha solucion

Country Status (26)

Country Link
US (1) US6306879B1 (es)
EP (1) EP1040838B1 (es)
JP (1) JP2000290180A (es)
KR (1) KR20010006930A (es)
CN (1) CN1270027A (es)
AR (1) AR023199A1 (es)
AT (1) ATE235256T1 (es)
AU (1) AU766250B2 (es)
BR (1) BR0001112A (es)
CA (1) CA2302886A1 (es)
CO (1) CO4970704A1 (es)
DE (1) DE50001522D1 (es)
DK (1) DK1040838T3 (es)
ES (1) ES2194640T3 (es)
HK (1) HK1033645A1 (es)
HU (1) HUP0001312A2 (es)
IL (1) IL135340A0 (es)
NO (1) NO20001658L (es)
NZ (1) NZ503428A (es)
PE (1) PE20001597A1 (es)
PL (1) PL339336A1 (es)
PT (1) PT1040838E (es)
RU (1) RU2238727C2 (es)
SI (1) SI1040838T1 (es)
SK (1) SK4632000A3 (es)
ZA (1) ZA200001618B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268148B2 (en) * 1999-05-20 2007-09-11 Regents Of The University Of Michigan Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
DE19957342A1 (de) * 1999-11-29 2001-05-31 Gruenenthal Gmbh Verfahren zur Behandlung und/oder Prophylaxe von IL-12-bedingten Erkrankungen
US7320991B2 (en) 2001-02-27 2008-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Analogs of thalidomide as potential angiogenesis inhibitors
CA2449671A1 (en) * 2001-06-06 2002-12-12 The Regents Of The University Of Michigan Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enyzmes
DE60231989D1 (de) * 2001-08-06 2009-05-28 Childrens Medical Center Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
EP1663223B1 (en) 2003-09-17 2014-01-01 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Thalidomide analogs as tnf-alpha modulators
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580641B1 (de) 1991-04-17 1996-12-27 Grünenthal GmbH Neue thalidomidderivate, ein verfahren zu deren herstellung sowie die verwendung derselben in arzneimitteln
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
DE19743968C2 (de) 1997-10-06 2002-07-11 Gruenenthal Gmbh Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen

Also Published As

Publication number Publication date
HK1033645A1 (en) 2001-09-14
SK4632000A3 (en) 2000-10-09
SI1040838T1 (en) 2003-08-31
ZA200001618B (en) 2000-10-25
KR20010006930A (ko) 2001-01-26
DE50001522D1 (de) 2003-04-30
ES2194640T3 (es) 2003-12-01
AU766250B2 (en) 2003-10-09
NO20001658L (no) 2000-10-02
AR023199A1 (es) 2002-09-04
BR0001112A (pt) 2001-08-21
HU0001312D0 (en) 2000-06-28
PL339336A1 (en) 2000-10-09
DK1040838T3 (da) 2003-05-26
JP2000290180A (ja) 2000-10-17
AU2420400A (en) 2000-10-05
EP1040838A1 (de) 2000-10-04
PT1040838E (pt) 2003-08-29
HUP0001312A2 (en) 2001-03-28
CA2302886A1 (en) 2000-09-30
ATE235256T1 (de) 2003-04-15
NO20001658D0 (no) 2000-03-30
CN1270027A (zh) 2000-10-18
CO4970704A1 (es) 2000-11-07
US6306879B1 (en) 2001-10-23
RU2238727C2 (ru) 2004-10-27
IL135340A0 (en) 2001-05-20
EP1040838B1 (de) 2003-03-26
NZ503428A (en) 2001-08-31

Similar Documents

Publication Publication Date Title
JP7328291B2 (ja) 貧血治療のための組成物及び方法
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
KR100258423B1 (ko) 오메프라졸 및 그의 동족체를 함유하는 주사제 및 주사제 키트
JP5565794B2 (ja) ピモベンダン及びシクロデキストリンの錯体を含む液体製剤
JP6466504B2 (ja) 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト
NO20064676L (no) Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre
US4942167A (en) Pharmaceutical compositions of piroxicam in aqueous solutions and process for their preparation
EA200700389A1 (ru) Стабильный при хранении инфузионный раствор дигидроптеридинонов
RS52374B (en) FORMS OF MEDICINES WITH IMPROVED PHARMACOKINETIC CHARACTERISTICS
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
CO5060477A1 (es) Forma de dosificacion de nefazodona
PE20001597A1 (es) Solucion acuosa estable de em 12 (3-(1-oxo-1,3-dihidro-isoindol-2-il)-piperidin-2,6-diona), y procedimiento de preparacion de dicha solucion
EA012836B1 (ru) Способ получения водорастворимых дитерпенов и их применение
RU2008146217A (ru) Фармацевтическая композиция, содержащая производное таксана, которая предназначена для приготовления инфузионного раствора, способ его приготовления и использование
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
CO5540278A2 (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
ES2233362T3 (es) Agentes para prevenir/tratar/inhibir el avance de retinopatia simple o retinopatia preproliferativa.
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)
JPH0789857A (ja) 水性懸濁液剤
ES2549309T3 (es) Formulación terapéutica nueva
ES2970909T3 (es) Composición farmacéutica para administración nasal que comprende rifampicinas para el tratamiento de la demencia
BRPI0713647A2 (pt) formulações farmacêuticas e composições de um antagonista seletivo cxcr2 ou cxcr1 e métodos para o uso do mesmo visando o tratamento de distúrbios inflamatórios
JPH0678241B2 (ja) ｔＰＡ医薬組成物
ES2322538T3 (es) Inhibidores contra el aumento de la tension ocular causada por irradiacion con laseres, que contienen derivados de 1,4-dihidropiridina.
NL8303549A (nl) Injectieoplossing en werkwijze voor het bereiden daarvan.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed